- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04852562
The Effect of Modified Radical Endoscopic Sinus Surgery on Eosinopilic Chronic Rhinosinusitus With Nasal Polyps (EMRESSECRS)
July 13, 2023 updated by: Zheng Liu
The Effect of Modified Radical Endoscopic Sinus Surgery on Chinese Patients With Eosinopilic Nasal Polyps
Functional endoscopic sinus surgery (FESS) is the pimary surgical treatment of CRS, characterized with the preservation of nasal structure and function.But the control of disease by surgery has been unsatisfactory.
Recent studies have shown that patients with recurrent CRSwNP (usually with severe eosinophilic inflammation), more radical surgery may be more effective.
The purpose of this prospective and randomized study is to determine the effect of endoscopic sinus surgery for extensive mucosal removal in patients with eosinophilic chronic rhinosinusitus with nasal polyps.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disorder that causes various symptoms including nasal obstruction, rhinorrhea, olfactory dysfunction, facial pain, and headache.
Patients with significant eosinophilic inflammation usually accompanied with a higher recurrence rate and more severe clinical symptoms.
Endoscopic sinus surgery (ESS) is recommended to patients who do not response well to conservative treatments.
A retrospective study showed that postoperative polyp recurrence rate of patients with severe eosinophilic inflammation was significantly reduced by rebooting sinus mucosa.
In this study, the experimental group intends to adopt a modified radical surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a extensive treatment of ethmoid sinus.
Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
Study Type
Interventional
Enrollment (Estimated)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zheng Liu, doctor
- Phone Number: 86 027 83663807
- Email: zhengliuent@hotmail.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Zheng Liu, doctor
- Phone Number: 86 027 83663807
- Email: zhengliuent@hotmail.com
-
Contact:
- Ming Zeng, Doctor
- Phone Number: 86 027 83663809
- Email: zmsx77@163.com
-
Principal Investigator:
- Zheng Liu, doctor
-
Principal Investigator:
- Heng Wang, doctor
-
Principal Investigator:
- Ming Zeng, Doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- CRSwNP is diagnosed according to EPOS clinical guidelines and met surgical requirements, the blood eosinophil count was greater than 0.22;
- Subjects/legal authorized representatives must understand the purpose and procedures of the study and voluntarily sign the informed consent, voluntarily participate in the study and comply with the study regulations, understand and comply with follow-up plan, and can correctly record the scale score, the administration frequency, accompanying drug use and adverse events, etc;
- The examinee must be 18-65 years old, male or non pregnant female, limited to Chinese;
- During the treatment and follow-up period, female subjects have no pregnancy and lactation plans;
- The subjects did not participate in other clinical trials in the past three months and agreed not to participate in other clinical trials before reaching the end point of this trial;
- Patients accompanying asthma must use their regular asthma treatment steadily in the past 6 weeks;
Exclusion Criteria:
- Women must not be pregnant, or breast-feeding;
- Subjects with cystic fibrosis, congenital ciliary dyskinesia, fungal sinusitis, systemic vasculitis and granulomatous disease, tumor, and immunodeficiency are exclued;
- Subjects accpted nasal endoscopic surgery within 6 months are exclued;
- Subjects with an upper respiratory tract infection within 4 weeks of entering the study are excluded;
- Subjects with serious metabolic, cardiovascular, autoimmune, neurology, blood, digestive, cerebrovascular, or respiratory system disease, or any disease interfering with the evaluation of results or affecting subjects safety are excluded, such as glaucoma and tuberculosis;
- Currently participating in other clinical studies or in other clinical investigators within 30 days, or staff directly involved in this study;
- Subjects with emotional or mental problems are excluded;
- Subjects must not have received immunotherapy within the previous 3 months;
- Subjects unsuitable for inclusion based on judgement of researchers are excluded;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Modified radical endoscopic sinus surgery(MRESS)
The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus.
Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
|
Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
Other Names:
|
Experimental: Functional endoscopic sinus surgery (FESS)
FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
|
Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline at months 1, 3, 6 and 12 in 22-item sino-nasaloutcome test (SNOT-22) scores after surgical intervention
Time Frame: 1month, 3month, 6month, 12month
|
The SNOT-22 is a validated questionnaire that was used to assess the impact of chronic rhinosinusitis on health-related quality of life (HRQoL).
It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be).
The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life.
|
1month, 3month, 6month, 12month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Revision surgery rate
Time Frame: 12month
|
The rate of reoperation in each group after surgery
|
12month
|
Symptom duration
Time Frame: 1month, 3month, 6month, 12month
|
The time of duration of major symptoms of postoperative patients
|
1month, 3month, 6month, 12month
|
Postoperative medication
Time Frame: 1month, 3month, 6month, 12month
|
The duration and dose of postoperative medication needed to relieve symptoms
|
1month, 3month, 6month, 12month
|
Recurrence time
Time Frame: 1month, 3month, 6month, 12month
|
Recurrence was defined if the patient had symptoms of chronic rhinosinusitis after surgery, and nasal endoscopy found nasal polyps recurrence, obvious edema of mucosa, or purulent secretion, and above of symptoms or physical signs existed, which can't be alleviated by maximum medicine treatment at least 1 month
|
1month, 3month, 6month, 12month
|
Change from baseline at months 1, 3, 6 and 12 in visual analogue scale (VAS) after surgical intervention
Time Frame: 1month, 3month, 6month, 12month
|
The VAS for rhinosinusitis was used to evaluate the total disease severity.
The participants were asked to indicate on a 10 centimeters (cm) VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?"
The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome.
|
1month, 3month, 6month, 12month
|
Change from baseline at months 1, 3, 6 and 12 in nasal endoscopic score after surgical intervention
Time Frame: 1month, 3month, 6month, 12month
|
Endoscopic result is scored according to Lund-Kennedy system, with the assessment of nasal polyp (NP), edema, nasal discharge, scarring and crusting.
Items including edema, nasal discharge, scarring and crusting score 0 for no problem, 1 for mild abnormalities and 2 for severe abnormalities.
NP score is graded and based on NP size recorded as the sum of the right and left nostril scores with a range of 0-8; higher scores indicate worse status.
Individual score ranges from 0 (no polyps) to 4 (large polyps causing almost complete congestion/ obstruction of the inferior meatus) within each nostril.
|
1month, 3month, 6month, 12month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline at months 1, 3, 6 and 12 in molecular indices of nasal lavage fluid
Time Frame: 1month, 3month, 6month, 12month
|
Investigate the change of inflammation molecular biomarkers using sample of nasal lavage fluid or mucosal lesion tissue.
Biomarkers including interleukin 9, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, macrophage inflammatory protein-1α, chemokine (C-C motif ) ligand 17 and IgE in nasal lavage fluid at months 1, 3, 6 and 12 were detected to compare the changes of molecular indices relative to baseline.
|
1month, 3month, 6month, 12month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 6, 2020
Primary Completion (Estimated)
December 6, 2023
Study Completion (Estimated)
December 6, 2024
Study Registration Dates
First Submitted
September 20, 2020
First Submitted That Met QC Criteria
April 17, 2021
First Posted (Actual)
April 21, 2021
Study Record Updates
Last Update Posted (Actual)
July 14, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENTmodifiedRESS-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Kaiser PermanenteWithdrawnChronic Sinusitis | Chronic Sinus Infection | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinus CongestionUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
Centre Hospitalier Intercommunal CreteilRecruitingSinusitis, Chronic | Sinus Infection ChronicFrance
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Australia
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)Poland, Australia, New Zealand, Austria, Czechia
-
Lyra TherapeuticsRecruitingChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Poland, Bulgaria, Belgium, Germany, Hungary
Clinical Trials on Modified radical endoscopic sinus surgery
-
Beijing Tongren HospitalCompletedChronic Rhinosinusitis (Diagnosis) | Surgery
-
Helsinki University Central HospitalActive, not recruitingAsthma | Nasal Polyps | Aspirin Sensitivity | Sinusitis, ChronicFinland, Netherlands
-
State University of New York - Upstate Medical...TerminatedChronic Sinusitis | Adenoid Disease - ChronicUnited States
-
Oregon Health and Science UniversityMedical University of South CarolinaActive, not recruitingChronic Rhinosinusitis | Olfactory Dysfunction
-
Instituto Nacional de Enfermedades RespiratoriasUnknownSleep | Aspirin-exacerbated Respiratory DiseaseMexico
-
University of California, San FranciscoCompletedAsthma | Chronic RhinosinusitisUnited States
-
Entellus Medical, Inc.CompletedChronic SinusitisUnited States
-
University Hospital, Strasbourg, FranceAssistance Publique - Hôpitaux de ParisTerminatedFrontal SinusitisFrance
-
IWitterickWithdrawnRhinosinusitis | Disorder of Maxillary Sinus | Aspirin-sensitive Asthma With Nasal PolypsCanada
-
Assiut UniversityNot yet recruitingAllergic Fungal Rhinosinusitis